21 May 2013
Keywords: merck, co, delays, filing, mk-524b, formulation, issue
Article | 09 October 2006
Merck & Co says it will delay filing an investigational triple combination cholesterol pill because of unspecified formulation
difficulties. The US ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 October 2006
16 October 2006
20 May 2013
© 2013 thepharmaletter.com